A Phase 2, Double-blind and Placebo Dose Ranging Study of Repeat Doses of AA4500 for the Treatment of Edematous Fibrosclerotic Panniculopathy
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 150
- 试验地点
- 10
- 主要终点
- Investigator Global Assessment of Aesthetic Improvement
研究概览
简要总结
To assess the safety and effectiveness of repeat doses of AA4500 in the treatment of edematous fibrosclerotic panniculopathy (EFP) commonly known as cellulite in adult women.
详细描述
The Phase 2a study is a randomized, double-blind multiple-dose study that is expected to enroll approximately 144 women between the ages of 18 and 45 in the United States. Treatment effectiveness will be evaluated by investigator and patient assessments, as well as 3-D photographic imaging techniques. Once the safety and local tolerability profile from the first stage has been found to be acceptable subjects will be enrolled in stage 2. After an interim safety and local tolerability review was completed of all subjects in stage 1, it was determined that enrollment in stage 2 is acceptable and has been initiated.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 45 Years（Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Be a female between 18 to 45 years of age.
- •Have at least one well defined dimple that is at least 1 cm but not more than 2 cm along the long axis and that is evident when the subject is standing
- •Have a photonumeric cellulite severity scale (CSS) score between 6 and 12
- •Have a Body Mass Index (BMI) >19 and <30 kg/m2, and intends to maintain stable body weight throughout the duration of the study
- •Be willing to apply appropriate sunscreen to the selected quadrant before each exposure to the sun while participating in the study
- •Be judged to be in good health, based upon the results of a medical history, physical examination, and laboratory profile at screening.
- •Have a negative urine pregnancy test at screening and before injection of AA4500 and be using an effective contraception method (ie, abstinence, intrauterine device [IUD], hormonal [estrogen/progestin] contraceptives, or barrier control) for at least one menstrual cycle prior to study enrollment and for the duration of the study.
- •Be willing and able to cooperate with the requirements of the study.
- •Voluntarily sign and date an informed consent agreement approved by the Institutional Review Board/Independent Ethics Committee/Human Research Ethics Committee (IRB/IEC/HREC).
- •Be able to read, complete and understand the Patient Reported Outcomes rating instruments in English.
排除标准
- •Thyroid disease, unless controlled with medication for ≥ 6 months
- •Uncontrolled diabetes mellitus, as determined by the investigator
- •Uncontrolled hypertension, as determined by the investigator
- •Vascular disorder (eg, phlebitis or varicose veins) in area to be treated
- •Lipedema or a lymphatic disorder
- •Cushing's disease and/or use of systemic corticosteroids
- •History of lower extremity thrombosis or post-thrombosis syndrome
- •Documented autoimmune disorder such as lupus erythematosus, rheumatoid arthritis
- •Inflammation or active infection in area to be treated
- •Cutaneous alteration in area to be treated
- •Rash, eczema, psoriasis, or skin cancer in the area to be treated
- •History of keloidal scarring or abnormal wound healing
- •Coagulation disorder
- •Taking a medication for chronic anticoagulation (except for ≤ 150 mg aspirin daily)
- •Known active hepatitis A, B or C
- •Known immune deficiency disease or a positive test for human immunodeficiency virus (HIV)
- •Other significant conditions including body dysmorphic disorder, which in the investigator's opinion would make the subject unsuitable for enrollment in the study
- •Is menopausal defined as 12 months of amenorrhea in the absence of other biological or physiological causes, as determined by the investigator
- •Has used any of the following for the treatment of EFP on the legs or buttock within the timelines identified below or intends to use any of the following at any time during the course of the study:
- •Liposuction on the side of the body selected for treatment during the 12-month period before injection of AA4500
- •Injections (eg, mesotherapy); radiofrequency device treatments; laser treatment; or surgery (including subcision) within the selected treatment quadrant during the 12-month period before injection of AA4500
- •Endermologie or similar treatments within the selected treatment quadrant during the 6-months period before injection of AA4500
- •Massage therapy within the selected treatment quadrant during the 3-month period before injection of AA4500
- •Creams (eg, Celluvera™, TriLastin®) to prevent or mitigate EFP within the selected treatment quadrant during the 2-week period before injection of AA4500
- •Has a tattoo located within 2 cm of the site of injection
- •Is presently nursing a baby or providing breast milk for a baby.
- •Intends to become pregnant during the study.
- •Intends to initiate an intensive sport or exercise program during the study.
- •Has received an investigational drug or treatment within 30 days before injection of AA
- •Has a known systemic allergy to collagenase or any other excipient of AA
- •Has received any collagenase treatments within 30 days before treatment.
研究组 & 干预措施
Placebo
Placebo
Each subject could receive up to three treatment sessions. Each treatment session was separated by approximately 21 days.
干预措施: Placebo (Biological)
AA4500 0.84 mg (high dose)
AA4500 (Collagenase Clostridium Histolyticum)
Each subject could receive up to three treatment sessions. Each treatment session was separated by approximately 21 days.
干预措施: Collagenase Clostridium Histolyticum (Biological)
AA4500 0.48 mg (mid-dose)
AA4500 (Collagenase Clostridium Histolyticum)
Each subject could receive up to three treatment sessions. Each treatment session was separated by approximately 21 days.
干预措施: Collagenase Clostridium Histolyticum (Biological)
AA4500 0.06 mg (low dose)
AA4500 (Collagenase Clostridium Histolyticum)
Each subject could receive up to three treatment sessions. Each treatment session was separated by approximately 21 days.
干预措施: Collagenase Clostridium Histolyticum (Biological)
结局指标
主要结局
Investigator Global Assessment of Aesthetic Improvement
时间窗: Baseline, Day 73
Investigators assessment of aesthetic improvement (I-GAIS) scores ranged from 3 to -1 as follows: 3 (very much improved), 2 (much improved), 1 (improved), 0 (no change), -1 (worse).
次要结局
未报告次要终点